Soutullo C A, Casuto L S, Keck P E
Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267-0559, USA.
J Child Adolesc Psychopharmacol. 1998;8(1):81-5. doi: 10.1089/cap.1998.8.81.
Gabapentin is a new antiepileptic drug with an unknown mechanism of action and very favorable pharmacokinetic and safety profiles. An increasing number of reports have described the successful use of gabapentin in bipolar disorder in adults. A 13-year-old boy with bipolar I disorder, manic episode, and ADHD, was treated with gabapentin 1,500 mg/day as add-on therapy to carbamazepine and showed a marked response within 1 month. He had previously failed a divalproex trial, could not tolerate lithium, and carbamazepine could not control his symptoms and induced a low WBC. He remained euthymic 7 months after gabapentin was added. His Young Mania Rating Scale (YMRS) score was 27 when gabapentin was added, 9 after 1 month, 15 after 4 months, and 6 after 7 months. Controlled studies are needed to evaluate the possible anti-manic, mood stabilizing, and/or anti-depressant properties of gabapentin in youth.
加巴喷丁是一种新型抗癫痫药物，其作用机制不明，但具有非常良好的药代动力学特性和安全性。越来越多的报告描述了加巴喷丁在成人双相情感障碍中的成功应用。一名患有双相I型障碍、躁狂发作和注意力缺陷多动障碍（ADHD）的13岁男孩，接受了加巴喷丁每日1500毫克的治疗，作为卡马西平的附加疗法，在1个月内显示出明显疗效。他之前丙戊酸治疗失败，无法耐受锂盐，卡马西平无法控制其症状且导致白细胞减少。加用加巴喷丁7个月后他一直保持心境正常。加用加巴喷丁时他的青年躁狂评定量表（YMRS）评分为27分，1个月后为9分，4个月后为15分，7个月后为6分。需要进行对照研究来评估加巴喷丁在青少年中可能的抗躁狂、心境稳定和/或抗抑郁特性。
